Collaborative Arrangements (Tables)

6 Months Ended

Jun. 30, 2018

Summarized information related to this collaboration is as follows:



($ in millions)	Three Months Ended June 30, 2018
Alliance revenues	$	35

Materials and production⁽¹⁾	1
Marketing and administrative	2
Research and development	36

($ in millions)	June 30, 2018
Receivables from Eisai	$	35
Payables to Eisai ⁽²⁾	677

⁽¹⁾Represents amortization of intangible assets.

⁽²⁾Includes accrued license option payments.

Summarized information related to this collaboration is as follows:



($ in millions)	Three Months Ended June 30, 2018		Six Months Ended June 30, 2018
Alliance revenues	$	44	$	76

Materials and production⁽¹⁾	24		36
Marketing and administrative	9		16
Research and development	42		71

($ in millions)	June 30, 2018		December 31, 2017
Receivables from AstraZeneca	$	40	$	12
Payables to AstraZeneca⁽²⁾	990		643

⁽¹⁾Represents amortization of intangible assets.

⁽²⁾Includes accrued milestone and license option payments.

Summarized information related to this collaboration is as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
($ in millions)	2018		2017		2018		2017
Net product sales recorded by Merck	$	47	$	36	$	90	$	67
Merck’s profit share from sales in Bayer's marketing territories	28		31		53		84
Total sales	75		67		143		151

Materials and production⁽¹⁾	132		24		159		47
Marketing and administrative	10		5		17		11
Research and development	28		25		56		51

($ in millions)					June 30, 2018		December 31, 2017
Receivables from Bayer					$	27	$	33
Payables to Bayer ⁽²⁾					375		352

⁽¹⁾Includes amortization of intangible assets.

⁽²⁾Includes accrued milestone payments.